SystImmune Inc. is a biopharmaceutical company focused on developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. Our objective is to create biologics that work through systematic intervention on tumor microenvironments, that directly attack the tumor and to activate the immune system to attack the tumor.
SystImmune-Inc is a US based enterprise company of the Sichuan Biokin Pharmaceutical Co., Ltd group. We are partnered with the venture capital firm OrbiMed and willing to seek parties interested in working with us to develop, commercialize, and bring our novel therapeutics to patients around the world.
We are a group of R&D and clinical scientists and biotech professionals utilizing several advanced technology platforms to develop world class antibody-based drug therapies. Our global clinical development strategy provides SystImmune’s drug programs multiple concurrent commercial opportunities that capitalize on US and Asia market efficiency.
Incorporation of binding domains into proprietary multi-specific antibody and ADC platforms, optimization of antibody properties such as humanness, stability, and binding and generation of high-quality antigen for a tailored antibody response.
Identification of monoclonal antibodies from rabbit and alpaca using B cell enrichment and sorting, or yeast display strategies enable selection of core assets with unique characteristics defined by screening using novel miniaturized immuno-assays.
Integrated and efficient titer optimizing CHO production platforms provide the foundation of our Downstream, Upstream, Formulation, and Analytical Group capability to manufacture our biotherapeutics.
As a clinical stage biotech company, SystImmune continues its highly active R&D programs. To produce future generations of breakthrough therapeutics from the Pacific North West.
Dr. Yi Zhu
President & CEO
